Luye Pharma Group Ltd.
🇨🇳China
Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects
Phase 1
Completed
- Conditions
- Huntington DiseaseTardive Dyskinesia
- Interventions
- Drug: LPM3770164 sustained release tabletDrug: LPM3770164 sustained release tablet simulant
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06216054
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Abdominal Surgery
Phase 2
Completed
- Conditions
- Pain, Postoperative
- Interventions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT06204120
- Locations
- 🇨🇳
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Relapsed Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 686
- Registration Number
- NCT06128837
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer
Phase 1
Completed
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06098599
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US-Prolia and EU-Prolia by Single-dose Subcutaneous Injection
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: LY06006 (Denosumab Biosimilar)Biological: US-Prolia (Denosumab)Biological: EU-Prolia
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT06095427
- Locations
- 🇩🇪
Parexel International GmbH, Early Phase Clinical Unit Berlin, Berlin, Germany
🇩🇪CTC North GmbH & Co KG, Hamburg, Germany
A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.
Phase 3
Recruiting
- Conditions
- Generalized Anxiety Disorder
- Interventions
- Drug: placeboDrug: Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mgDrug: Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 555
- Registration Number
- NCT05970510
- Locations
- 🇨🇳
Peking University Sixth Hospital, Beijing, China
Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors
Phase 1
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: LY010616
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT05865925
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Dose-escalation Study of LPM3480392 in Chinese Healthy Subjects
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05862974
- Locations
- 🇨🇳
The second affiliated hosipital zhejiang university school of medicine, Hangzhou, Zhejiang, China
An Exploratory Study of LPM3480392 at Different Infusion Rates in Chinese Healthy Subjects
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT05857449
- Locations
- 🇨🇳
The second affiliated hosipital zhejiang university school of medicine, Hangzhou, Zhejiang, China
Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg
Phase 1
Not yet recruiting
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05856630
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China
© Copyright 2025. All Rights Reserved by MedPath